Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD70 CAR-NK (Zhejiang University)
- Development stage
- Unknown
- Lead developer
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This investigational cell therapy consists of cord blood-derived natural killer (NK) cells engineered to express a chimeric antigen receptor (CAR) targeting CD70. Developed by the Second Affiliated Hospital, School of Medicine, Zhejiang University, the therapy is designed to treat relapsed or refractory T-cell lymphoma (TCL) and acute myeloid leukemia (AML). CD70 is a surface protein overexpressed in various hematological malignancies but found at low levels in normal tissues, making it a viable target for immunotherapy. By utilizing NK cells instead of T cells, the therapy aims to provide potent anti-tumor activity while potentially reducing the risks of graft-versus-host disease (GvHD) and cytokine release syndrome (CRS). It is currently undergoing Phase 1 clinical evaluation for safety and efficacy.
- Other names
- Cord blood-derived CD70-targeting CAR-NK cell therapyCD70-CAR-NKCD-70-CAR-NKCD 70-CAR-NK
02
Targets
CD70 (Cluster of Differentiation 70)
Beyond the preview
Go deeper on CD70 CAR-NK (Zhejiang University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD70 CAR-NK (Zhejiang University).